Ocular Therapeutix Shares Soar After AXPAXLI Hits SOL-1 Phase 3 Endpoint in Wet AMD
Ocular Therapeutix’s lead candidate AXPAXLI achieved its primary efficacy endpoint in the SOL-1 Phase 3 trial for wet age-related macular degeneration, prompting a 50% surge in its shares on Feb. 24. This milestone advances AXPAXLI toward a potential regulatory submission pending full data analysis.
1. Trial Milestone and Market Reaction
AXPAXLI met the SOL-1 Phase 3 trial’s primary efficacy endpoint in patients with wet age-related macular degeneration, marking the first late-stage success for Ocular Therapeutix in this indication. News of the positive top-line result drove a 50% jump in the company’s share price on Feb. 24, reflecting strong investor confidence in AXPAXLI’s commercial prospects and its potential to address unmet needs in wet AMD treatment.
Related News
META
Manus Founders Seek $1B Raise to Unwind Meta's $2B AI Acquisition
META•
CRM
Salesforce Faces Competition from Nvidia’s $200B AI CPU, Nasdaq Rally
CRM•
JEPI
Active ETFs Shift Holdings Daily, Provide Downside Protection, Charge 0.4%-1% Fees
JEPI•
NVDA
Nvidia’s AI Chip Revenue Forecast Beats Estimates but Shares Drop 1.3%
NVDA•
MMYT
MakeMyTrip Q4 Cash Hits $782M with 1.82% Margin and 15.2% Accommodation Growth
MMYT•
Sources
F